SPX -0.58% VIX 4.38%
WAR OF WILL WINS 144TH PREAKNESS IN RACE THAT INCLUDED RIDERLESS HORSE
MICHIGAN GOP CONGRESSMAN SEEN AS FIRST OF PARTY TO SAY TRUMP ACTS IMPEACHABLE
AOC STANDS WITH BUFFETT: CEO NET WORTH SHOULD TAKE A HIT IF BAILOUT GIVEN
JOE BIDEN PITCHES HIMSELF AS A UNITER EVEN AS HE TEARS INTO TRUMP
HERE'S THE STOCK PLAY BOOSTED BY 'GAME OF THRONES' BANDWIDTH HOGS
THE TARIFF TIFF AND A FED RETHINK ARE JUST TWO AREAS OF STOCK-MARKET ANGST
ECONOMIC PREVIEW: CONSUMER SPENDING SLOWS, INVESTMENT HURT BY CHINA TRADE WAR
STRATEGIST: A NUMBER OF INDICATORS SUGGEST THE STOCK MARKET COULD EXTEND GAINS
AUSTRALIAS RULING CONSERVATIVE COALITION APPEARS HEADED TO A SURPRISE WIN
U.S. STOCKS END LOWER FOR DAY AND WEEK ON U.S.-CHINA TRADE UNCERTAINTY
Mon, May 20 5:07am

Biotech And Pharma Industry Stocks 0

These Biotech And Pharma Industry Stocks are listed on the Nasdaq or NYSE exchange.

View key information like the 1 year chart, stock price, market capitalization, earnings date, earnings per share, price to earnings ratio, dividend yield and ex-dividend date.

Click on the column headings to sort the data.



Screener
Min must be less than the Max.
Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

AbbVie Inc [ABBV]
$79.46 0.04 (0.05%)

ABBV Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 117.47 Billion
ABBV Description

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013.


Visit Website

ABBV Earnings

EPS 1.65 P/E Ratio 22.14
Previous Earnings Fri, Jan 25, 2019
Latest Earnings Thu, Apr 25, 2019 (25 days ago)

ABBV Dividend

Yield 5.39% / $4.28
Ex-Date Fri, Apr 12, 2019 (38 days ago)
Pay Date Wed, May 15, 2019
History 26 Payments (Quarterly)

ABBV Charts

$76.87
52 Week Range
$106.23
May 13, 2019
May 21, 2018

79.46 117.47 22.14 5.39 ABBV NYSE -0.05 -10.95 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABBV&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABBV&exchange=NYSE&chart=1

Allergan PLC [AGN]
$140.20 0.16 (0.11%)

AGN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 46.04 Billion
AGN Description

Allergan is one of the largest specialty pharmaceutical manufacturers. It specializes in aesthetics, ophthalmology, women's health, gastrointestinal, and central nervous system products. In 2016, Allergan sold its generics and distribution segments to Teva.


Visit Website

AGN Earnings

EPS -7.25 P/E Ratio 0.00
Previous Earnings Tue, Jan 29, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

AGN Dividend

Yield 2.11% / $2.96
Ex-Date Mon, May 13, 2019 (7 days ago)
Pay Date Fri, Jun 14, 2019
History 10 Payments (Quarterly)

AGN Charts

$129.82
52 Week Range
$193.46
Dec 24, 2018
Oct 3, 2018

140.20 46.04 0.00 2.11 AGN NYSE 0.11 3.18 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGN&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGN&exchange=NYSE&chart=1

Alexion Pharmaceuticals Inc [ALXN]
$130.90 0.50 (0.38%)

ALXN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 29.46 Billion
ALXN Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. Next-generation Ultomiris was recently approved in paroxysmal nocturnal hemoglobinuria. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need and complement-mediated disorders.


Visit Website

ALXN Earnings

EPS 2.63 P/E Ratio 392.83
Previous Earnings Mon, Feb 4, 2019
Latest Earnings Thu, Apr 25, 2019 (25 days ago)

ALXN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALXN Charts

$93.94
52 Week Range
$141.30
Dec 24, 2018
Apr 10, 2019

130.90 29.46 392.83 0.00 ALXN NASDAQ -0.38 33.50 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALXN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALXN&exchange=NASDAQ&chart=1

Amgen Inc [AMGN]
$169.91 0.01 (0.01%)

AMGN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 103.64 Billion
AMGN Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).


Visit Website

AMGN Earnings

EPS 3.20 P/E Ratio 15.15
Previous Earnings Tue, Jan 29, 2019
Latest Earnings Tue, Apr 30, 2019 (20 days ago)

AMGN Dividend

Yield 3.41% / $5.80
Ex-Date Thu, May 16, 2019 (4 days ago)
Pay Date Fri, Jun 7, 2019
History 32 Payments (Quarterly)

AMGN Charts

$167.60
52 Week Range
$208.89
May 13, 2019
Sep 27, 2018

169.91 103.64 15.15 3.41 AMGN NASDAQ -0.01 -11.46 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMGN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMGN&exchange=NASDAQ&chart=1

Biogen Inc [BIIB]
$229.28 1.59 (0.69%)

BIIB Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 44.91 Billion
BIIB Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.


Visit Website

BIIB Earnings

EPS 7.17 P/E Ratio 10.77
Previous Earnings Tue, Jan 29, 2019
Latest Earnings Wed, Apr 24, 2019 (26 days ago)

BIIB Dividend

Yield --
Ex-Date --
Pay Date --
History --

BIIB Charts

$216.71
52 Week Range
$383.83
Mar 22, 2019
Jul 25, 2018

229.28 44.91 10.77 0.00 BIIB NASDAQ -0.69 -24.75 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BIIB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BIIB&exchange=NASDAQ&chart=1

BioMarin Pharmaceutical Inc [BMRN]
$88.71 0.96 (1.07%)

BMRN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 15.89 Billion
BMRN Description

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.


Visit Website

BMRN Earnings

EPS -0.32 P/E Ratio 0.00
Previous Earnings Thu, Feb 21, 2019
Latest Earnings Thu, Apr 25, 2019 (25 days ago)

BMRN Dividend

Yield --
Ex-Date --
Pay Date --
History --

BMRN Charts

$80.14
52 Week Range
$106.07
Dec 24, 2018
Oct 17, 2018

88.71 15.89 0.00 0.00 BMRN NASDAQ -1.07 4.41 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMRN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMRN&exchange=NASDAQ&chart=1

Bristol-Myers Squibb Co [BMY]
$46.85 0.27 (0.57%)

BMY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 76.63 Billion
BMY Description

Bristol-Myers Squibb Co discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs.


Visit Website

BMY Earnings

EPS 1.05 P/E Ratio 15.35
Previous Earnings Thu, Jan 24, 2019
Latest Earnings Thu, Apr 25, 2019 (25 days ago)

BMY Dividend

Yield 3.50% / $1.64
Ex-Date Thu, Apr 4, 2019 (46 days ago)
Pay Date Wed, May 1, 2019
History 134 Payments (Quarterly)

BMY Charts

$44.62
52 Week Range
$63.23
Apr 24, 2019
Oct 9, 2018

46.85 76.63 15.35 3.50 BMY NYSE -0.57 -9.94 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMY&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=BMY&exchange=NYSE&chart=1

Celgene Corp [CELG]
$95.42 0.09 (0.09%)

CELG Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 67.36 Billion
CELG Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.


Visit Website

CELG Earnings

EPS 2.20 P/E Ratio 17.70
Previous Earnings Thu, Jan 31, 2019
Latest Earnings Thu, Apr 25, 2019 (25 days ago)

CELG Dividend

Yield --
Ex-Date --
Pay Date --
History --

CELG Charts

$59.21
52 Week Range
$96.88
Dec 24, 2018
May 3, 2019

95.42 67.36 17.70 0.00 CELG NASDAQ -0.09 43.19 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CELG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CELG&exchange=NASDAQ&chart=1

Endo International PLC [ENDP]
$6.52 0.08 (1.21%)

ENDP Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.49 Billion
ENDP Description

After a string of acquisitions and divestitures, Endo is a specialty pharmaceutical company with a considerable presence in pain management. The acquisitions of Auxilium and Par increased the company's presence in urology and generics, respectively.


Visit Website

ENDP Earnings

EPS -0.08 P/E Ratio 0.00
Previous Earnings Thu, Feb 28, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ENDP Dividend

Yield --
Ex-Date --
Pay Date --
History --

ENDP Charts

$5.95
52 Week Range
$18.30
May 22, 2018
Oct 16, 2018

6.52 1.49 0.00 0.00 ENDP NASDAQ -1.21 -15.43 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ENDP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ENDP&exchange=NASDAQ&chart=1

Gilead Sciences Inc [GILD]
$66.36 0.58 (0.88%)

GILD Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 83.64 Billion
GILD Description

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.


Visit Website

GILD Earnings

EPS 1.55 P/E Ratio 55.20
Previous Earnings Mon, Feb 4, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

GILD Dividend

Yield 3.44% / $2.28
Ex-Date Thu, Dec 13, 2018 (158 days ago)
Pay Date Fri, Dec 28, 2018
History 15 Payments (Quarterly)

GILD Charts

$60.54
52 Week Range
$79.00
Dec 24, 2018
Oct 3, 2018

66.36 83.64 55.20 3.44 GILD NASDAQ 0.88 4.60 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=GILD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=GILD&exchange=NASDAQ&chart=1

Incyte Corp [INCY]
$77.20 0.44 (0.57%)

INCY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 16.55 Billion
INCY Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.


Visit Website

INCY Earnings

EPS 0.48 P/E Ratio 145.02
Previous Earnings Thu, Feb 14, 2019
Latest Earnings Tue, Apr 30, 2019 (20 days ago)

INCY Dividend

Yield --
Ex-Date --
Pay Date --
History --

INCY Charts

$58.50
52 Week Range
$88.17
Dec 24, 2018
Mar 1, 2019

77.20 16.55 145.02 0.00 INCY NASDAQ -0.57 21.46 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=INCY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=INCY&exchange=NASDAQ&chart=1

Johnson & Johnson [JNJ]
$138.61 0.40 (0.29%)

JNJ Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 366.96 Billion
JNJ Description

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.


Visit Website

JNJ Earnings

EPS 1.41 P/E Ratio 24.34
Previous Earnings Tue, Apr 16, 2019
Latest Earnings Tue, Jul 16, 2019 (In 57 days)

JNJ Dividend

Yield 2.74% / $3.80
Ex-Date Fri, May 24, 2019 (In 4 days)
Pay Date Tue, Jun 11, 2019
History 190 Payments (Quarterly)

JNJ Charts

$119.40
52 Week Range
$147.84
May 29, 2018
Dec 13, 2018

138.61 366.96 24.34 2.74 JNJ NYSE 0.29 8.50 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=JNJ&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=JNJ&exchange=NYSE&chart=1

Eli Lilly & Co [LLY]
$116.01 0.72 (0.62%)

LLY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 112.63 Billion
LLY Description

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.


Visit Website

LLY Earnings

EPS 4.33 P/E Ratio 40.60
Previous Earnings Tue, Apr 30, 2019
Latest Earnings Tue, Jul 30, 2019 (In 71 days)

LLY Dividend

Yield 2.22% / $2.58
Ex-Date Thu, May 16, 2019 (4 days ago)
Pay Date Mon, Jun 10, 2019
History 134 Payments (Quarterly)

LLY Charts

$81.83
52 Week Range
$131.02
May 21, 2018
Mar 26, 2019

116.01 112.63 40.60 2.22 LLY NYSE -0.62 0.98 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=LLY&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=LLY&exchange=NYSE&chart=1

Mallinckrodt PLC [MNK]
$14.68 0.48 (3.17%)

MNK Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.23 Billion
MNK Description

Mallinckrodt PLC is a specialty pharmaceutical company that was spun off from Covidien and historically focused on pain therapeutics. After recently moving its generics business into discontinued operations, Mallinckrodt now focuses entirely on branded drugs following the sale of its nuclear imaging business in 2016. Mallinckrodt's products now span a number of therapeutic areas, but a significant portion focus on hospital and clinical customers.


Visit Website

MNK Earnings

EPS 1.86 P/E Ratio 0.00
Previous Earnings Tue, Feb 26, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

MNK Dividend

Yield --
Ex-Date --
Pay Date --
History --

MNK Charts

$14.68
52 Week Range
$36.08
May 17, 2019
Aug 23, 2018

14.68 1.23 0.00 0.00 MNK NYSE -3.17 -11.51 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MNK&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MNK&exchange=NYSE&chart=1

Merck & Co Inc [MRK]
$78.72 0.41 (0.52%)

MRK Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 202.68 Billion
MRK Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to half of the company's sales are generated in the United States.


Visit Website

MRK Earnings

EPS 1.13 P/E Ratio 33.85
Previous Earnings Tue, Apr 30, 2019
Latest Earnings Tue, Jul 30, 2019 (In 71 days)

MRK Dividend

Yield 2.79% / $2.20
Ex-Date Thu, Mar 14, 2019 (67 days ago)
Pay Date Fri, Apr 5, 2019
History 134 Payments (Quarterly)

MRK Charts

$58.40
52 Week Range
$83.30
May 29, 2018
Apr 1, 2019

78.72 202.68 33.85 2.79 MRK NYSE -0.52 4.14 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MRK&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MRK&exchange=NYSE&chart=1

Mylan NV [MYL]
$19.64 0.57 (2.82%)

MYL Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 10.12 Billion
MYL Description

Mylan is one of the world's largest generic pharmaceutical manufacturers with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales constitute approximately 90% of revenue. Remaining sales come from a handful of branded products, primarily epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.


Visit Website

MYL Earnings

EPS -0.05 P/E Ratio 28.88
Previous Earnings Tue, Feb 26, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

MYL Dividend

Yield --
Ex-Date --
Pay Date --
History 73 Payments (Quarterly)

MYL Charts

$19.64
52 Week Range
$41.86
May 17, 2019
Jun 12, 2018

19.64 10.12 28.88 0.00 MYL NASDAQ -2.82 -29.66 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MYL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=MYL&exchange=NASDAQ&chart=1

Pfizer Inc [PFE]
$41.47 0.17 (0.41%)

PFE Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 231.52 Billion
PFE Description

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drugs Enbrel and Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total company sales.


Visit Website

PFE Earnings

EPS 0.69 P/E Ratio 11.28
Previous Earnings Tue, Jan 29, 2019
Latest Earnings Tue, Apr 30, 2019 (20 days ago)

PFE Dividend

Yield 3.47% / $1.44
Ex-Date Thu, May 9, 2019 (11 days ago)
Pay Date Fri, Jun 7, 2019
History 134 Payments (Quarterly)

PFE Charts

$35.68
52 Week Range
$46.23
May 25, 2018
Nov 30, 2018

41.47 231.52 11.28 3.47 PFE NYSE -0.41 -4.12 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PFE&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PFE&exchange=NYSE&chart=1

Perrigo Co PLC [PRGO]
$49.67 0.23 (0.46%)

PRGO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 6.75 Billion
PRGO Description

Perrigo is the largest store-brand over-the-counter pharmaceutical and infant formula manufacturer. The company operates three major segments: consumer healthcare, branded consumer healthcare, and prescription pharmaceuticals. As of mid-2018, Perrigo plans to divest the prescription segment. In the United States, Perrigo sells about 2,100 products with 9,000 stock-keeping units. Following the acquisition of Omega Pharma, approximately 30% of the company's revenue comes from outside the U.S.


Visit Website

PRGO Earnings

EPS 0.59 P/E Ratio 67.25
Previous Earnings Wed, Feb 27, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

PRGO Dividend

Yield 1.69% / $0.84
Ex-Date Thu, May 30, 2019 (In 10 days)
Pay Date Tue, Jun 18, 2019
History 66 Payments (Quarterly)

PRGO Charts

$36.50
52 Week Range
$80.52
Dec 24, 2018
Jul 31, 2018

49.67 6.75 67.25 1.69 PRGO NYSE -0.46 22.64 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PRGO&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=PRGO&exchange=NYSE&chart=1

Regeneron Pharmaceuticals Inc [REGN]
$304.94 3.10 (1.01%)

REGN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 33.96 Billion
REGN Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.


Visit Website

REGN Earnings

EPS 4.23 P/E Ratio 24.20
Previous Earnings Wed, Feb 6, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

REGN Dividend

Yield --
Ex-Date --
Pay Date --
History --

REGN Charts

$293.74
52 Week Range
$439.57
May 25, 2018
Mar 1, 2019

304.94 33.96 24.20 0.00 REGN NASDAQ -1.01 -18.12 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=REGN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=REGN&exchange=NASDAQ&chart=1

Vertex Pharmaceuticals Inc [VRTX]
$168.73 1.50 (0.88%)

VRTX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 43.91 Billion
VRTX Description

Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, and Symdeko for cystic fibrosis, in addition to several pipeline candidates targeting this market. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases.


Visit Website

VRTX Earnings

EPS 1.05 P/E Ratio 20.79
Previous Earnings Tue, Feb 5, 2019
Latest Earnings Tue, Apr 30, 2019 (20 days ago)

VRTX Dividend

Yield --
Ex-Date --
Pay Date --
History --

VRTX Charts

$145.72
52 Week Range
$194.70
Jun 5, 2018
Jan 18, 2019

168.73 43.91 20.79 0.00 VRTX NASDAQ -0.88 2.83 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=VRTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=VRTX&exchange=NASDAQ&chart=1

Zoetis Inc [ZTS]
$101.97 0.96 (0.93%)

ZTS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 48.81 Billion
ZTS Description

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns more than 55% of total revenue from production animals (cattle, pigs, poultry, and so on), and companion animal (dogs, horses, cats) products make up the remainder. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.


Visit Website

ZTS Earnings

EPS 0.65 P/E Ratio 34.56
Previous Earnings Thu, Feb 14, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

ZTS Dividend

Yield 0.64% / $0.66
Ex-Date Thu, Jul 18, 2019 (In 59 days)
Pay Date Tue, Sep 3, 2019
History 26 Payments (Quarterly)

ZTS Charts

$79.28
52 Week Range
$103.75
Dec 24, 2018
May 3, 2019

101.97 48.81 34.56 0.64 ZTS NYSE -0.93 20.70 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ZTS&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ZTS&exchange=NYSE&chart=1

Shire PLC (ADR) [SHPG]
$179.20 0.00 (0.00%)

SHPG Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 33.15 Billion
SHPG Description

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.


Visit Website

SHPG Earnings

EPS 1.77 P/E Ratio 11.36
Previous Earnings --
Latest Earnings Thu, Nov 1, 2018 (200 days ago)

SHPG Dividend

Yield 0.19% / $0.34
Ex-Date Thu, Sep 6, 2018 (256 days ago)
Pay Date Fri, Oct 19, 2018
History 5 Payments (Biannual)

SHPG Charts

$156.98
52 Week Range
$181.95
Jun 19, 2018
Nov 12, 2018

179.20 33.15 11.36 0.19 SHPG NASDAQ 0.00 3.76 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SHPG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SHPG&exchange=NASDAQ&chart=1

Nektar Therapeutics [NKTR]
$32.02 0.68 (2.17%)

NKTR Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 5.58 Billion
NKTR Description

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.


Visit Website

NKTR Earnings

EPS -0.68 P/E Ratio 8.20
Previous Earnings Thu, Feb 28, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

NKTR Dividend

Yield --
Ex-Date --
Pay Date --
History --

NKTR Charts

$30.43
52 Week Range
$90.35
Dec 24, 2018
Jun 1, 2018

32.02 5.58 8.20 0.00 NKTR NASDAQ 2.17 -6.43 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=NKTR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=NKTR&exchange=NASDAQ&chart=1

Sanofi SA (ADR) [SNY]
$41.90 0.24 (0.58%)

SNY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 104.41 Billion
SNY Description

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just under 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of sales.


Visit Website

SNY Earnings

EPS 0.46 P/E Ratio 21.78
Previous Earnings Fri, Apr 26, 2019
Latest Earnings Mon, Jul 29, 2019 (In 70 days)

SNY Dividend

Yield 4.15% / $1.74
Ex-Date Tue, May 7, 2019 (13 days ago)
Pay Date Fri, May 31, 2019
History 19 Payments (Annually)

SNY Charts

$37.85
52 Week Range
$45.59
May 29, 2018
Nov 9, 2018

41.90 104.41 21.78 4.15 SNY NYSE 0.58 -2.24 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SNY&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=SNY&exchange=NYSE&chart=1

Teva Pharmaceutical Industries Ltd (ADR) ADR [TEVA]
$11.63 0.21 (1.84%)

TEVA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 12.79 Billion
TEVA Description

Headquartered in Israel, Teva Pharmaceutical is one of the world's largest generic pharmaceutical manufacturers. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent about 55% of total revenue, with branded drug and distribution revenue making up the balance of sales. Prior to generic competition, Copaxone made up about half of Teva's branded drug segment, with about $4 billion in annual sales.


Visit Website

TEVA Earnings

EPS -0.10 P/E Ratio 0.00
Previous Earnings Wed, Feb 13, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

TEVA Dividend

Yield --
Ex-Date --
Pay Date --
History 132 Payments (Quarterly)

TEVA Charts

$11.42
52 Week Range
$25.65
May 16, 2019
Aug 20, 2018

11.63 12.79 0.00 0.00 TEVA NYSE 1.84 -26.62 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=TEVA&exchange=NYSE&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=TEVA&exchange=NYSE&chart=1

Abeona Therapeutics Inc [ABEO]
$7.44 0.01 (0.13%)

ABEO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 370 Million
ABEO Description

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. The gene therapy involves the use of DNA as a potential therapy to treat a disease. The company's initial programs are focused on lysosomal storage diseases such as Mucopolysaccharidosis (MPS) IIIA and IIIB. It is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases.


Visit Website

ABEO Earnings

EPS -0.39 P/E Ratio 0.00
Previous Earnings Mon, Mar 18, 2019
Latest Earnings Fri, May 10, 2019 (10 days ago)

ABEO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ABEO Charts

$6.38
52 Week Range
$18.75
Feb 21, 2019
May 30, 2018

7.44 0.37 0.00 0.00 ABEO NASDAQ -0.13 5.83 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABEO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABEO&exchange=NASDAQ&chart=1

ARCA biopharma Inc [ABIO]
$9.41 0.11 (1.18%)

ABIO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
ABIO Description

ARCA biopharma Inc is a biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The firm's lead product candidate is Gencaro. The company adopts genotype-directed comparative effectiveness trial of Bucindolol and Toprol-XL for prevention of symptomatic atrial fibrillation in patients with heart failure. It establishes long-term relationships with partners such as Medtronic, Laboratory Corporation of America and the University of Colorado.


Visit Website

ABIO Earnings

EPS -1.86 P/E Ratio 0.00
Previous Earnings --
Latest Earnings --

ABIO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ABIO Charts

$5.04
52 Week Range
$18.36
Dec 27, 2018
Oct 1, 2018

9.41 0.02 0.00 0.00 ABIO NASDAQ 1.18 58.42 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABIO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABIO&exchange=NASDAQ&chart=1

Arbutus Biopharma Corp [ABUS]
$2.40 0.06 (2.44%)

ABUS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 140 Million
ABUS Description

Arbutus Biopharma Corp is a pharmaceutical company. It discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.


Visit Website

ABUS Earnings

EPS -0.47 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Mon, May 6, 2019 (14 days ago)

ABUS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ABUS Charts

$2.20
52 Week Range
$12.35
May 13, 2019
Aug 2, 2018

2.40 0.14 0.00 0.00 ABUS NASDAQ -2.44 -40.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABUS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ABUS&exchange=NASDAQ&chart=1

ACADIA Pharmaceuticals Inc [ACAD]
$25.03 0.63 (2.46%)

ACAD Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 3.61 Billion
ACAD Description

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.


Visit Website

ACAD Earnings

EPS -0.59 P/E Ratio 0.00
Previous Earnings Tue, Feb 26, 2019
Latest Earnings Wed, May 1, 2019 (19 days ago)

ACAD Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACAD Charts

$13.03
52 Week Range
$28.12
Aug 17, 2018
Apr 5, 2019

25.03 3.61 0.00 0.00 ACAD NASDAQ -2.46 50.33 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACAD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACAD&exchange=NASDAQ&chart=1

Acer Therapeutics Inc. - Common Stock [ACER]
$19.12 2.12 (9.98%)

ACER Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 190 Million
ACER Description

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes two categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.


Visit Website

ACER Earnings

EPS -0.79 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Tue, May 14, 2019 (6 days ago)

ACER Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACER Charts

$16.55
52 Week Range
$32.83
Dec 24, 2018
Aug 22, 2018

19.12 0.19 0.00 0.00 ACER NASDAQ -9.98 -10.86 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACER&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACER&exchange=NASDAQ&chart=1

Achillion Pharmaceuticals Inc [ACHN]
$3.06 0.00 (0.00%)

ACHN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 420 Million
ACHN Description

Achillion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on advancing oral small molecule complement system inhibitors into late-stage development and commercialization.


Visit Website

ACHN Earnings

EPS -0.14 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ACHN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACHN Charts

$1.31
52 Week Range
$3.89
Dec 24, 2018
Oct 3, 2018

3.06 0.42 0.00 0.00 ACHN NASDAQ 0.00 81.07 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHN&exchange=NASDAQ&chart=1

ACHIEVE LIFE SCIENCE INC [ACHV]
$3.49 0.34 (8.88%)

ACHV Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
ACHV Description

Achieve Life Sciences Inc is a United States based clinical-stage biopharmaceutical company. It is focused on the development of novel next-generation cancer therapeutics. The company's product candidate is apatorsen which is designed to block the production of heat shock protein 27, or Hsp27, a protein that promotes treatment resistance in cancer. The group has business offices located in Bothell, Washington and Vancouver, British Columbia.


Visit Website

ACHV Earnings

EPS -0.55 P/E Ratio 0.72
Previous Earnings --
Latest Earnings --

ACHV Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACHV Charts

$1.16
52 Week Range
$11.80
Jan 14, 2019
May 21, 2018

3.49 0.02 0.72 0.00 ACHV NASDAQ -8.88 172.66 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHV&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACHV&exchange=NASDAQ&chart=1

AC Immune SA [ACIU]
$5.09 0.06 (1.17%)

ACIU Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 340 Million
ACIU Description

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.


Visit Website

ACIU Earnings

EPS -0.21 P/E Ratio 0.00
Previous Earnings Thu, Mar 21, 2019
Latest Earnings Wed, May 15, 2019 (5 days ago)

ACIU Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACIU Charts

$3.65
52 Week Range
$16.46
Jan 30, 2019
Jul 25, 2018

5.09 0.34 0.00 0.00 ACIU NASDAQ -1.17 -50.20 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACIU&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACIU&exchange=NASDAQ&chart=1

Acorda Therapeutics Inc [ACOR]
$11.02 0.51 (4.42%)

ACOR Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 530 Million
ACOR Description

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders.Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Visit Website

ACOR Earnings

EPS -1.00 P/E Ratio 0.00
Previous Earnings Thu, Feb 14, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

ACOR Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACOR Charts

$10.05
52 Week Range
$32.60
May 1, 2019
Jun 11, 2018

11.02 0.53 0.00 0.00 ACOR NASDAQ -4.42 -32.06 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACOR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACOR&exchange=NASDAQ&chart=1

Aclaris Therapeutics Inc [ACRS]
$5.64 0.12 (2.08%)

ACRS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 230 Million
ACRS Description

Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.


Visit Website

ACRS Earnings

EPS -0.91 P/E Ratio 0.00
Previous Earnings Mon, Mar 18, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ACRS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACRS Charts

$5.19
52 Week Range
$20.89
Apr 17, 2019
Jul 11, 2018

5.64 0.23 0.00 0.00 ACRS NASDAQ -2.08 -26.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACRS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACRS&exchange=NASDAQ&chart=1

Acasti Pharma, Inc. - Class A Common Stock [ACST]
$0.86 0.00 (0.00%)

ACST Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
ACST Description

Acasti Pharma Inc is a biopharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. The company operates through the single segment being Development and commercialization of prescription drugs.


Visit Website

ACST Earnings

EPS -0.07 P/E Ratio 0.00
Previous Earnings Wed, Nov 14, 2018
Latest Earnings Thu, Feb 14, 2019 (95 days ago)

ACST Dividend

Yield --
Ex-Date --
Pay Date --
History --

ACST Charts

$0.45
52 Week Range
$1.57
Aug 16, 2018
Oct 1, 2018

0.86 0.07 0.00 0.00 ACST NASDAQ 0.00 -4.44 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACST&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ACST&exchange=NASDAQ&chart=1

Adaptimmune Therapeutics PLC [ADAP]
$3.67 0.02 (0.54%)

ADAP Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 380 Million
ADAP Description

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.


Visit Website

ADAP Earnings

EPS -0.24 P/E Ratio 0.00
Previous Earnings Wed, Feb 27, 2019
Latest Earnings Mon, May 6, 2019 (14 days ago)

ADAP Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADAP Charts

$3.63
52 Week Range
$14.16
Mar 22, 2019
Oct 4, 2018

3.67 0.38 0.00 0.00 ADAP NASDAQ -0.54 -33.75 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADAP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADAP&exchange=NASDAQ&chart=1

Adial Pharmaceuticals Inc [ADIL]
$2.26 0.01 (0.44%)

ADIL Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 20 Million
ADIL Description

Adial Pharmaceuticals Inc is a United States-based pharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is an approved drug for treating nausea and emesis.


Visit Website

ADIL Earnings

EPS -0.33 P/E Ratio 0.00
Previous Earnings Mon, Sep 10, 2018
Latest Earnings Wed, Nov 14, 2018 (187 days ago)

ADIL Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADIL Charts

$1.21
52 Week Range
$8.33
Nov 14, 2018
Jan 15, 2019

2.26 0.02 0.00 0.00 ADIL NASDAQ 0.44 -65.23 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADIL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADIL&exchange=NASDAQ&chart=1

ADMA Biologics Inc [ADMA]
$4.03 0.19 (4.50%)

ADMA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 230 Million

ADMA Earnings

EPS -0.28 P/E Ratio 0.00
Previous Earnings Wed, Mar 13, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ADMA Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADMA Charts

$2.17
52 Week Range
$6.85
Dec 26, 2018
Sep 5, 2018

4.03 0.23 0.00 0.00 ADMA NASDAQ -4.50 53.82 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADMA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADMA&exchange=NASDAQ&chart=1

Aduro Biotech Inc [ADRO]
$3.13 0.06 (1.88%)

ADRO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 250 Million
ADRO Description

Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.


Visit Website

ADRO Earnings

EPS -0.29 P/E Ratio 0.00
Previous Earnings Wed, Feb 27, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

ADRO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADRO Charts

$2.42
52 Week Range
$8.80
Jan 28, 2019
May 31, 2018

3.13 0.25 0.00 0.00 ADRO NASDAQ -1.88 14.65 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADRO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADRO&exchange=NASDAQ&chart=1

Adverum Biotechnologies Inc [ADVM]
$9.05 0.92 (11.32%)

ADVM Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 530 Million
ADVM Description

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.


Visit Website

ADVM Earnings

EPS -0.23 P/E Ratio 0.00
Previous Earnings Wed, Mar 6, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ADVM Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADVM Charts

$2.87
52 Week Range
$9.05
Dec 21, 2018
May 17, 2019

9.05 0.53 0.00 0.00 ADVM NASDAQ 11.32 165.40 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADVM&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADVM&exchange=NASDAQ&chart=1

Advaxis Inc [ADXS]
$3.12 0.10 (3.31%)

ADXS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million

ADXS Earnings

EPS 2.70 P/E Ratio 0.00
Previous Earnings Tue, Jan 15, 2019
Latest Earnings Tue, Mar 12, 2019 (69 days ago)

ADXS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ADXS Charts

$2.78
52 Week Range
$28.50
Dec 24, 2018
Jun 7, 2018

3.12 0.03 0.00 0.00 ADXS NASDAQ 3.31 -29.57 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADXS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ADXS&exchange=NASDAQ&chart=1

Aeterna Zentaris Inc. - Common Stock [AEZS]
$3.17 0.13 (3.94%)

AEZS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
AEZS Description

AEterna Zentaris Inc is a specialty biopharmaceutical company. It is involved in development and commercialization of novel pharmaceutical therapies, drug development activities and promotion of products for others in oncology, endocrinology and women's health. The company focuses on the acquisition of licenses to products that are relevant to their therapeutic areas of focus. Its primary product is Apifiny. It is developing Macrilen, Zoptrex and AEZS drugs in the pipeline.


Visit Website

AEZS Earnings

EPS -0.30 P/E Ratio 5.30
Previous Earnings Tue, Mar 26, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

AEZS Dividend

Yield --
Ex-Date --
Pay Date --
History --

AEZS Charts

$1.30
52 Week Range
$5.43
Oct 24, 2018
Apr 4, 2019

3.17 0.05 5.30 0.00 AEZS NASDAQ -3.94 4.62 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AEZS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AEZS&exchange=NASDAQ&chart=1

Affimed NV [AFMD]
$3.37 0.12 (3.44%)

AFMD Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 270 Million

AFMD Earnings

EPS 0.15 P/E Ratio 0.00
Previous Earnings Wed, Nov 7, 2018
Latest Earnings Wed, Mar 27, 2019 (54 days ago)

AFMD Dividend

Yield --
Ex-Date --
Pay Date --
History --

AFMD Charts

$1.45
52 Week Range
$6.15
Aug 14, 2018
Aug 29, 2018

3.37 0.27 0.00 0.00 AFMD NASDAQ -3.44 4.66 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AFMD&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AFMD&exchange=NASDAQ&chart=1

Agenus Inc [AGEN]
$2.95 0.00 (0.00%)

AGEN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 400 Million
AGEN Description

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharp & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.


Visit Website

AGEN Earnings

EPS 0.14 P/E Ratio 0.00
Previous Earnings Thu, Mar 14, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

AGEN Dividend

Yield --
Ex-Date --
Pay Date --
History --

AGEN Charts

$1.59
52 Week Range
$3.73
Aug 20, 2018
Jan 17, 2019

2.95 0.40 0.00 0.00 AGEN NASDAQ 0.00 17.53 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGEN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGEN&exchange=NASDAQ&chart=1

Agios Pharmaceuticals Inc [AGIO]
$50.10 0.36 (0.72%)

AGIO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 2.94 Billion
AGIO Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.


Visit Website

AGIO Earnings

EPS -1.59 P/E Ratio 0.00
Previous Earnings Thu, Feb 14, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

AGIO Dividend

Yield --
Ex-Date --
Pay Date --
History --

AGIO Charts

$42.73
52 Week Range
$99.55
Dec 21, 2018
Jun 20, 2018

50.10 2.94 0.00 0.00 AGIO NASDAQ 0.72 6.03 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGIO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGIO&exchange=NASDAQ&chart=1

Aeglea BioTherapeutics Inc [AGLE]
$6.48 0.39 (5.68%)

AGLE Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 190 Million
AGLE Description

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.


Visit Website

AGLE Earnings

EPS -0.59 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

AGLE Dividend

Yield --
Ex-Date --
Pay Date --
History --

AGLE Charts

$6.48
52 Week Range
$11.00
May 17, 2019
Jul 2, 2018

6.48 0.19 0.00 0.00 AGLE NASDAQ -5.68 -19.40 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGLE&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGLE&exchange=NASDAQ&chart=1

Applied Genetic Technologies Corp [AGTC]
$3.82 0.06 (1.55%)

AGTC Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
AGTC Description

Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 & ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.


Visit Website

AGTC Earnings

EPS 0.63 P/E Ratio 0.00
Previous Earnings Thu, Feb 7, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

AGTC Dividend

Yield --
Ex-Date --
Pay Date --
History --

AGTC Charts

$2.28
52 Week Range
$7.35
Dec 21, 2018
Sep 27, 2018

3.82 0.07 0.00 0.00 AGTC NASDAQ -1.55 44.15 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGTC&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AGTC&exchange=NASDAQ&chart=1

Aimmune Therapeutics Inc [AIMT]
$20.11 0.54 (2.62%)

AIMT Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.26 Billion
AIMT Description

Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.


Visit Website

AIMT Earnings

EPS -0.87 P/E Ratio 0.00
Previous Earnings Thu, Feb 28, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

AIMT Dividend

Yield --
Ex-Date --
Pay Date --
History --

AIMT Charts

$19.64
52 Week Range
$33.20
May 7, 2019
May 24, 2018

20.11 1.26 0.00 0.00 AIMT NASDAQ -2.62 -17.38 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AIMT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AIMT&exchange=NASDAQ&chart=1

Achaogen Inc [AKAO]
$0.00 0.00 (0.00%)

AKAO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
AKAO Description

Achaogen Inc is a biopharmaceutical company developing novel antibacterial treatments against multi-drug resistant gram-negative infections. The company is researching and developing on its product plazomicin used for the treatment of serious bacterial infections. It's another antibacterial candidate, C-Scape treats patients with urinary tract infections. All of the company's revenue is generated from government contracts for research and development in the United States.


Visit Website

AKAO Earnings

EPS -1.01 P/E Ratio 0.00
Previous Earnings Thu, Nov 8, 2018
Latest Earnings Thu, Mar 28, 2019 (53 days ago)

AKAO Dividend

Yield --
Ex-Date --
Pay Date --
History --

AKAO Charts

$33.65
52 Week Range
$37.10
Jan 3, 2019
Jun 21, 2018

0.00 0.01 0.00 0.00 AKAO NASDAQ 0.00 -100.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKAO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKAO&exchange=NASDAQ&chart=1

Akebia Therapeutics Inc [AKBA]
$5.50 0.12 (2.14%)

AKBA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 650 Million
AKBA Description

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.


Visit Website

AKBA Earnings

EPS -0.76 P/E Ratio 0.00
Previous Earnings Mon, Mar 18, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

AKBA Dividend

Yield --
Ex-Date --
Pay Date --
History --

AKBA Charts

$5.39
52 Week Range
$11.34
Dec 28, 2018
Jun 20, 2018

5.50 0.65 0.00 0.00 AKBA NASDAQ -2.14 -5.17 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKBA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKBA&exchange=NASDAQ&chart=1

Akcea Therapeutics Inc [AKCA]
$20.68 1.05 (4.83%)

AKCA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.92 Billion
AKCA Description

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.


Visit Website

AKCA Earnings

EPS 0.35 P/E Ratio 0.00
Previous Earnings Mon, Nov 5, 2018
Latest Earnings Tue, Feb 26, 2019 (83 days ago)

AKCA Dividend

Yield --
Ex-Date --
Pay Date --
History --

AKCA Charts

$20.68
52 Week Range
$38.99
May 17, 2019
Aug 7, 2018

20.68 1.92 0.00 0.00 AKCA NASDAQ -4.83 -32.70 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKCA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKCA&exchange=NASDAQ&chart=1

Akari Therapeutics PLC [AKTX]
$2.76 0.18 (6.12%)

AKTX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
AKTX Description

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. The firm earns majority of its revenues from United Kingdom. It operates mainly in United States and United Kingdom.


Visit Website

AKTX Earnings

EPS -0.22 P/E Ratio 0.00
Previous Earnings Thu, Nov 15, 2018
Latest Earnings Tue, Apr 23, 2019 (27 days ago)

AKTX Dividend

Yield --
Ex-Date --
Pay Date --
History --

AKTX Charts

$1.57
52 Week Range
$5.90
Dec 31, 2018
Mar 13, 2019

2.76 0.04 0.00 0.00 AKTX NASDAQ -6.12 65.27 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AKTX&exchange=NASDAQ&chart=1

Albireo Pharma, Inc. - Common Stock [ALBO]
$35.98 1.78 (4.71%)

ALBO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 430 Million
ALBO Description

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.


Visit Website

ALBO Earnings

EPS -1.34 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ALBO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALBO Charts

$20.90
52 Week Range
$37.86
Dec 21, 2018
May 15, 2019

35.98 0.43 0.00 0.00 ALBO NASDAQ -4.71 49.11 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALBO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALBO&exchange=NASDAQ&chart=1

Alder BioPharmaceuticals Inc [ALDR]
$10.83 0.15 (1.37%)

ALDR Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 900 Million
ALDR Description

Alder BioPharmaceuticals Inc is a biotechnology company that seeks to discover, develop, and commercialize therapeutic antibodies. The company's antibody platform seeks to maximize efficacy, as well as the speed of onset and durability of therapeutic response. Alder's product pipeline addresses diseases where patients have limited medical options or where current medical options may not meet the needs of a substantial number of patients. The company operates in three geographic regions: the United States, Australia, and Ireland. The vast majority of the Alder's assets are located in the United States, where the vast majority of its revenue is also generated.


Visit Website

ALDR Earnings

EPS -1.63 P/E Ratio 0.00
Previous Earnings Mon, Feb 25, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

ALDR Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALDR Charts

$9.80
52 Week Range
$19.90
Dec 21, 2018
Aug 8, 2018

10.83 0.90 0.00 0.00 ALDR NASDAQ -1.37 -0.82 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDR&exchange=NASDAQ&chart=1

Aldeyra Therapeutics Inc [ALDX]
$7.30 0.06 (0.82%)

ALDX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 200 Million
ALDX Description

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.


Visit Website

ALDX Earnings

EPS -0.58 P/E Ratio 0.00
Previous Earnings Fri, Mar 8, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ALDX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALDX Charts

$6.80
52 Week Range
$14.35
Jul 30, 2018
Sep 27, 2018

7.30 0.20 0.00 0.00 ALDX NASDAQ -0.82 -14.22 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALDX&exchange=NASDAQ&chart=1

Alkermes PLC [ALKS]
$24.85 0.45 (1.78%)

ALKS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 3.90 Billion
ALKS Description

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.


Visit Website

ALKS Earnings

EPS -0.62 P/E Ratio 0.00
Previous Earnings Thu, Feb 14, 2019
Latest Earnings Thu, Apr 25, 2019 (25 days ago)

ALKS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALKS Charts

$24.85
52 Week Range
$51.36
May 17, 2019
Jun 20, 2018

24.85 3.90 0.00 0.00 ALKS NASDAQ -1.78 -14.63 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALKS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALKS&exchange=NASDAQ&chart=1

Allakos Inc [ALLK]
$43.22 0.46 (1.08%)

ALLK Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.86 Billion
ALLK Description

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.


Visit Website

ALLK Earnings

EPS -0.47 P/E Ratio 0.00
Previous Earnings Thu, Mar 14, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ALLK Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALLK Charts

$31.25
52 Week Range
$62.65
Jul 19, 2018
Dec 10, 2018

43.22 1.86 0.00 0.00 ALLK NASDAQ 1.08 -16.87 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLK&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLK&exchange=NASDAQ&chart=1

Allogene Therapeutics Inc [ALLO]
$29.19 0.57 (1.92%)

ALLO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 3.55 Billion
ALLO Description

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.


Visit Website

ALLO Earnings

EPS -0.32 P/E Ratio 0.00
Previous Earnings Fri, Mar 8, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

ALLO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALLO Charts

$22.50
52 Week Range
$33.30
Oct 24, 2018
Nov 6, 2018

29.19 3.55 0.00 0.00 ALLO NASDAQ -1.92 5.91 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALLO&exchange=NASDAQ&chart=1

Allena Pharmaceuticals Inc [ALNA]
$5.25 0.37 (6.58%)

ALNA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 110 Million
ALNA Description

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.


Visit Website

ALNA Earnings

EPS -0.55 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ALNA Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALNA Charts

$5.11
52 Week Range
$15.99
Dec 24, 2018
May 21, 2018

5.25 0.11 0.00 0.00 ALNA NASDAQ -6.58 -18.35 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNA&exchange=NASDAQ&chart=1

Alnylam Pharmaceuticals Inc [ALNY]
$67.54 1.19 (1.73%)

ALNY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 7.20 Billion
ALNY Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran for amyloidosis, Alnylam has partnered several pipeline candidates, including hemophilia drug fitusiran, and cholesterol drug inclisiran. Up-front fees from research partnerships with firms such as Sanofi, Takeda, Roche, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see milestones and royalties from drugs commercialized under these agreements.


Visit Website

ALNY Earnings

EPS -1.73 P/E Ratio 0.00
Previous Earnings Thu, Feb 7, 2019
Latest Earnings Wed, May 1, 2019 (19 days ago)

ALNY Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALNY Charts

$62.67
52 Week Range
$122.67
Dec 24, 2018
Aug 31, 2018

67.54 7.20 0.00 0.00 ALNY NASDAQ -1.73 -7.17 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALNY&exchange=NASDAQ&chart=1

Alpine Management Systems Inc [ALPN]
$5.95 0.41 (7.40%)

ALPN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 110 Million
ALPN Description

Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.


Visit Website

ALPN Earnings

EPS -0.80 P/E Ratio 0.00
Previous Earnings Mon, Mar 18, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ALPN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALPN Charts

$3.68
52 Week Range
$10.05
Dec 31, 2018
May 21, 2018

5.95 0.11 0.00 0.00 ALPN NASDAQ 7.40 45.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALPN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALPN&exchange=NASDAQ&chart=1

Aileron Therapeutics Inc [ALRN]
$1.24 0.09 (6.77%)

ALRN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
ALRN Description

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Its lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers. It reactivates p53-mediated tumor suppression by targeting the two primary p53 suppressor proteins, MDMX and MDM2.


Visit Website

ALRN Earnings

EPS -0.49 P/E Ratio 0.00
Previous Earnings Fri, Mar 29, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ALRN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ALRN Charts

$0.71
52 Week Range
$6.04
Dec 21, 2018
Jun 22, 2018

1.24 0.03 0.00 0.00 ALRN NASDAQ -6.77 21.57 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALRN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALRN&exchange=NASDAQ&chart=1

Altimmune, Inc. - Common Stock [ALT]
$2.45 0.16 (6.13%)

ALT Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
ALT Description

Altimmune Inc is a United States-based clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, NasoShield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.


Visit Website

ALT Earnings

EPS -2.79 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Wed, May 15, 2019 (5 days ago)

ALT Dividend

Yield --
Ex-Date --
Pay Date --
History 9 Payments (Biannual)

ALT Charts

$1.72
52 Week Range
$26.23
Dec 24, 2018
Sep 20, 2018

2.45 0.04 0.00 0.00 ALT NASDAQ -6.13 -5.77 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ALT&exchange=NASDAQ&chart=1

AMAG Pharmaceuticals Inc [AMAG]
$10.34 0.44 (4.08%)

AMAG Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 360 Million
AMAG Description

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.


Visit Website

AMAG Earnings

EPS -3.54 P/E Ratio 0.00
Previous Earnings Thu, Feb 7, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

AMAG Dividend

Yield --
Ex-Date --
Pay Date --
History --

AMAG Charts

$10.34
52 Week Range
$25.65
May 17, 2019
Aug 10, 2018

10.34 0.36 0.00 0.00 AMAG NASDAQ -4.08 -34.31 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMAG&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMAG&exchange=NASDAQ&chart=1

Amarin Corp PLC [AMRN]
$17.79 0.40 (2.30%)

AMRN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 5.75 Billion
AMRN Description

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular health. Its products include Vascepa. The firm has Development and Commercialization of Vascepa operating segment. It mainly operates in the United States.


Visit Website

AMRN Earnings

EPS -0.07 P/E Ratio 0.00
Previous Earnings Wed, Feb 27, 2019
Latest Earnings Wed, May 1, 2019 (19 days ago)

AMRN Dividend

Yield --
Ex-Date --
Pay Date --
History --

AMRN Charts

$2.45
52 Week Range
$22.98
Jul 30, 2018
Nov 5, 2018

17.79 5.75 0.00 0.00 AMRN NASDAQ 2.30 36.74 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMRN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AMRN&exchange=NASDAQ&chart=1

AnaptysBio Inc [ANAB]
$70.92 1.63 (2.25%)

ANAB Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.96 Billion
ANAB Description

AnaptysBio Inc is a US-based clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.


Visit Website

ANAB Earnings

EPS -0.64 P/E Ratio 0.00
Previous Earnings Thu, Feb 28, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

ANAB Dividend

Yield --
Ex-Date --
Pay Date --
History --

ANAB Charts

$55.40
52 Week Range
$101.95
Dec 21, 2018
Sep 24, 2018

70.92 1.96 0.00 0.00 ANAB NASDAQ -2.25 11.30 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANAB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANAB&exchange=NASDAQ&chart=1

Anika Therapeutics Inc [ANIK]
$36.93 0.08 (0.22%)

ANIK Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 520 Million
ANIK Description

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.


Visit Website

ANIK Earnings

EPS 0.32 P/E Ratio 25.30
Previous Earnings Thu, Feb 21, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

ANIK Dividend

Yield --
Ex-Date --
Pay Date --
History --

ANIK Charts

$28.77
52 Week Range
$46.12
Jun 20, 2018
Jun 19, 2018

36.93 0.52 25.30 0.00 ANIK NASDAQ -0.22 6.98 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIK&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIK&exchange=NASDAQ&chart=1

ANI Pharmaceuticals Inc [ANIP]
$69.92 0.46 (0.65%)

ANIP Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 840 Million
ANIP Description

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.


Visit Website

ANIP Earnings

EPS 0.04 P/E Ratio 52.65
Previous Earnings Wed, Feb 27, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ANIP Dividend

Yield --
Ex-Date --
Pay Date --
History --

ANIP Charts

$41.17
52 Week Range
$73.19
Dec 21, 2018
May 10, 2019

69.92 0.84 52.65 0.00 ANIP NASDAQ -0.65 52.56 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ANIP&exchange=NASDAQ&chart=1

Apellis Pharmaceuticals Inc [APLS]
$18.00 0.53 (2.86%)

APLS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.14 Billion
APLS Description

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.


Visit Website

APLS Earnings

EPS -0.87 P/E Ratio 0.00
Previous Earnings Tue, Feb 26, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

APLS Dividend

Yield --
Ex-Date --
Pay Date --
History --

APLS Charts

$11.47
52 Week Range
$24.21
Oct 24, 2018
Jun 19, 2018

18.00 1.14 0.00 0.00 APLS NASDAQ -2.86 32.16 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APLS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APLS&exchange=NASDAQ&chart=1

Cellect Biotechnology Ltd. - American Depositary Shares [APOP]
$0.63 0.05 (7.35%)

APOP Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap --
APOP Description

Cellect Biotechnology Ltd is a biotechnology company engaged in developing a novel technology platform. The company is engaged in the development of an innovative, unique technology that enables the biological filtering and commercialization of stem cells.


Visit Website

APOP Earnings

EPS -0.58 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Tue, Nov 13, 2018 (188 days ago)

APOP Dividend

Yield --
Ex-Date --
Pay Date --
History --

APOP Charts

$0.63
52 Week Range
$7.47
May 17, 2019
Jun 1, 2018

0.63 0.00 0.00 0.00 APOP NASDAQ -7.35 -72.73 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APOP&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APOP&exchange=NASDAQ&chart=1

Apricus Biosciences Inc [APRI]
$6.60 0.20 (2.94%)

APRI Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 10 Million
APRI Description

Apricus Biosciences Inc is engaged in the pharmaceutical industry. The company develops and commercializes products and product candidates in the areas of urology and rheumatology. Apricus' drug delivery technology is a permeation enhancer called NexACT. The company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon.


Visit Website

APRI Earnings

EPS -0.12 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Thu, Aug 9, 2018 (284 days ago)

APRI Dividend

Yield --
Ex-Date --
Pay Date --
History --

APRI Charts

$5.65
52 Week Range
$14.54
Dec 26, 2018
Jun 19, 2018

6.60 0.01 0.00 0.00 APRI NASDAQ -2.94 -8.97 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APRI&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APRI&exchange=NASDAQ&chart=1

Aptose Biosciences, Inc. - Common Shares [APTO]
$2.09 0.06 (2.96%)

APTO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 90 Million
APTO Description

Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm has CG-806, APTO-253 drugs in preclinical development stage pipeline.


Visit Website

APTO Earnings

EPS -0.14 P/E Ratio 0.00
Previous Earnings Tue, Mar 12, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

APTO Dividend

Yield --
Ex-Date --
Pay Date --
History --

APTO Charts

$1.61
52 Week Range
$4.50
Mar 6, 2019
Jun 18, 2018

2.09 0.09 0.00 0.00 APTO NASDAQ 2.96 -5.00 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTO&exchange=NASDAQ&chart=1

Aptinyx Inc [APTX]
$3.51 0.12 (3.31%)

APTX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 120 Million
APTX Description

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.


Visit Website

APTX Earnings

EPS -0.50 P/E Ratio 0.00
Previous Earnings Thu, Mar 21, 2019
Latest Earnings Tue, May 14, 2019 (6 days ago)

APTX Dividend

Yield --
Ex-Date --
Pay Date --
History --

APTX Charts

$3.51
52 Week Range
$31.85
May 17, 2019
Sep 10, 2018

3.51 0.12 0.00 0.00 APTX NASDAQ -3.31 -79.65 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APTX&exchange=NASDAQ&chart=1

Aptevo Therapeutics Inc [APVO]
$0.79 0.00 (0.00%)

APVO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
APVO Description

Aptevo Therapeutics Inc is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, ROR1 Candidate, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.


Visit Website

APVO Earnings

EPS -0.44 P/E Ratio 0.00
Previous Earnings Mon, Mar 18, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

APVO Dividend

Yield --
Ex-Date --
Pay Date --
History --

APVO Charts

$0.70
52 Week Range
$5.65
May 2, 2019
Jun 21, 2018

0.79 0.04 0.00 0.00 APVO NASDAQ 0.00 -44.37 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APVO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=APVO&exchange=NASDAQ&chart=1

AquaBounty Technologies Inc [AQB]
$2.12 0.02 (0.95%)

AQB Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
AQB Description

AquaBounty Technologies Inc is a biotechnology company. It is engaged in research, development, and commercialization of the commercial viability of a group of proteins, antifreeze proteins. The company primarily focuses on the managing aquaculture productivity. Its lead product is the AquAdvantage Salmon, a genetically modified animal for human consumption. Geographically, all the operation of the group is functioned through the region of US and it derives revenue from the sale of AquAdvantage Salmon.


Visit Website

AQB Earnings

EPS -0.18 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Thu, May 2, 2019 (18 days ago)

AQB Dividend

Yield --
Ex-Date --
Pay Date --
History --

AQB Charts

$1.68
52 Week Range
$4.89
Dec 28, 2018
Mar 8, 2019

2.12 0.05 0.00 0.00 AQB NASDAQ 0.95 -11.30 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQB&exchange=NASDAQ&chart=1

Aquestive Therapeutics Inc [AQST]
$5.05 0.06 (1.17%)

AQST Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 130 Million
AQST Description

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.


Visit Website

AQST Earnings

EPS -0.59 P/E Ratio 0.00
Previous Earnings Thu, Mar 14, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

AQST Dividend

Yield --
Ex-Date --
Pay Date --
History --

AQST Charts

$4.52
52 Week Range
$18.96
May 8, 2019
Sep 7, 2018

5.05 0.13 0.00 0.00 AQST NASDAQ -1.17 -29.67 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQST&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AQST&exchange=NASDAQ&chart=1

Aravive, Inc. - Common Stock [ARAV]
$6.38 0.27 (4.42%)

ARAV Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
ARAV Description

Aravive Inc is a clinical stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. The company's lead candidate AVB-S6-500 is developed as a targeted therapy against ovarian cancer.


Visit Website

ARAV Earnings

EPS -0.42 P/E Ratio 4.57
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ARAV Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARAV Charts

$3.23
52 Week Range
$14.70
Dec 27, 2018
Jun 15, 2018

6.38 0.07 4.57 0.00 ARAV NASDAQ 4.42 75.27 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARAV&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARAV&exchange=NASDAQ&chart=1

Arcturus Therapeutics Ltd. - Ordinary Shares [ARCT]
$6.23 0.06 (0.97%)

ARCT Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 70 Million
ARCT Description

Arcturus Therapeutics Ltd is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF and LUNAR-2020.


Visit Website

ARCT Earnings

EPS -0.68 P/E Ratio 0.00
Previous Earnings Mon, Mar 18, 2019
Latest Earnings Mon, May 13, 2019 (7 days ago)

ARCT Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARCT Charts

$4.11
52 Week Range
$9.80
Dec 28, 2018
Sep 21, 2018

6.23 0.07 0.00 0.00 ARCT NASDAQ 0.97 32.84 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARCT&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARCT&exchange=NASDAQ&chart=1

Aridis Pharmaceuticals Inc [ARDS]
$9.40 0.00 (0.00%)

ARDS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 80 Million
ARDS Description

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.


Visit Website

ARDS Earnings

EPS -0.67 P/E Ratio 0.00
Previous Earnings Thu, Mar 28, 2019
Latest Earnings Tue, May 14, 2019 (6 days ago)

ARDS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARDS Charts

$7.82
52 Week Range
$13.69
Dec 11, 2018
Sep 4, 2018

9.40 0.08 0.00 0.00 ARDS NASDAQ 0.00 -10.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDS&exchange=NASDAQ&chart=1

Ardelyx Inc [ARDX]
$2.99 0.09 (2.92%)

ARDX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 190 Million
ARDX Description

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.


Visit Website

ARDX Earnings

EPS -0.42 P/E Ratio 0.00
Previous Earnings Wed, Mar 6, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

ARDX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARDX Charts

$1.66
52 Week Range
$5.65
Dec 24, 2018
May 21, 2018

2.99 0.19 0.00 0.00 ARDX NASDAQ -2.92 49.50 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARDX&exchange=NASDAQ&chart=1

argenx SE - American Depositary Shares [ARGX]
$128.63 1.73 (1.33%)

ARGX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 4.95 Billion
ARGX Description

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-113, ARGX-110, ARGX-115, ARGX-112 etc. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Luxembourg.


Visit Website

ARGX Earnings

EPS -0.08 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Thu, Oct 25, 2018 (207 days ago)

ARGX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARGX Charts

$63.81
52 Week Range
$134.59
Oct 10, 2018
Mar 1, 2019

128.63 4.95 0.00 0.00 ARGX NASDAQ -1.33 30.13 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARGX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARGX&exchange=NASDAQ&chart=1

Arena Pharmaceuticals Inc [ARNA]
$54.01 1.81 (3.24%)

ARNA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 2.77 Billion
ARNA Description

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.


Visit Website

ARNA Earnings

EPS 12.53 P/E Ratio 0.00
Previous Earnings Tue, Feb 26, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ARNA Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARNA Charts

$32.52
52 Week Range
$55.96
Nov 14, 2018
May 15, 2019

54.01 2.77 0.00 0.00 ARNA NASDAQ -3.24 34.29 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARNA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARNA&exchange=NASDAQ&chart=1

Aerpio Pharmaceuticals Inc [ARPO]
$1.01 0.02 (1.94%)

ARPO Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 40 Million
ARPO Description

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company' product AKB-9778, is a Tie2 activator being developed for the treatment of diabetic eye disease. Other products under the pipeline are cc-1536 and c-4924.


Visit Website

ARPO Earnings

EPS -0.21 P/E Ratio 0.00
Previous Earnings Tue, Mar 5, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ARPO Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARPO Charts

$0.90
52 Week Range
$4.55
Mar 29, 2019
Jun 25, 2018

1.01 0.04 0.00 0.00 ARPO NASDAQ -1.94 -49.25 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARPO&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARPO&exchange=NASDAQ&chart=1

Arqule Inc [ARQL]
$6.78 0.25 (3.56%)

ARQL Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 770 Million
ARQL Description

Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Geographically, the firm operates through the region of United States.


Visit Website

ARQL Earnings

EPS -0.09 P/E Ratio 0.00
Previous Earnings Thu, Mar 7, 2019
Latest Earnings Wed, May 1, 2019 (19 days ago)

ARQL Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARQL Charts

$2.26
52 Week Range
$7.03
Dec 21, 2018
May 16, 2019

6.78 0.77 0.00 0.00 ARQL NASDAQ -3.56 134.60 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARQL&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARQL&exchange=NASDAQ&chart=1

Array BioPharma Inc [ARRY]
$21.86 0.03 (0.14%)

ARRY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 4.84 Billion
ARRY Description

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.


Visit Website

ARRY Earnings

EPS -0.17 P/E Ratio 0.00
Previous Earnings Tue, Feb 5, 2019
Latest Earnings Tue, May 7, 2019 (13 days ago)

ARRY Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARRY Charts

$12.92
52 Week Range
$24.85
Oct 10, 2018
Apr 3, 2019

21.86 4.84 0.00 0.00 ARRY NASDAQ 0.14 46.71 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARRY&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARRY&exchange=NASDAQ&chart=1

Arvinas Inc [ARVN]
$22.25 0.24 (1.09%)

ARVN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 710 Million
ARVN Description

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases.


Visit Website

ARVN Earnings

EPS -0.46 P/E Ratio 0.00
Previous Earnings Tue, Mar 26, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ARVN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARVN Charts

$11.19
52 Week Range
$23.79
Dec 24, 2018
Feb 15, 2019

22.25 0.71 0.00 0.00 ARVN NASDAQ 1.09 61.12 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARVN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARVN&exchange=NASDAQ&chart=1

Arrowhead Pharmaceuticals Inc [ARWR]
$19.46 0.01 (0.05%)

ARWR Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.85 Billion
ARWR Description

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.


Visit Website

ARWR Earnings

EPS 0.25 P/E Ratio 0.00
Previous Earnings Thu, Feb 7, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ARWR Dividend

Yield --
Ex-Date --
Pay Date --
History --

ARWR Charts

$9.74
52 Week Range
$20.30
May 22, 2018
Sep 10, 2018

19.46 1.85 0.00 0.00 ARWR NASDAQ -0.05 48.32 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARWR&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ARWR&exchange=NASDAQ&chart=1

ASLAN Pharmaceuticals Limited - American Depositary Shares [ASLN]
$3.60 0.10 (2.70%)

ASLN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 120 Million
ASLN Description

ASLAN Pharmaceuticals Ltd is a clinical-stage oncology-focused biotechnology company. It is developing novel therapeutics for global markets. The company's portfolio consists of four product candidates which target validated growth pathways applied to new patient segments and novel cancer metabolic pathways. The company targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.


Visit Website

ASLN Earnings

EPS -0.36 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Mon, Apr 29, 2019 (21 days ago)

ASLN Dividend

Yield --
Ex-Date --
Pay Date --
History --

ASLN Charts

$2.86
52 Week Range
$10.24
Dec 24, 2018
Jun 7, 2018

3.60 0.12 0.00 0.00 ASLN NASDAQ -2.70 -13.25 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASLN&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASLN&exchange=NASDAQ&chart=1

Assembly Biosciences Inc [ASMB]
$15.22 0.60 (3.79%)

ASMB Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 390 Million
ASMB Description

Assembly Biosciences Inc is a clinical stage biotechnology company. It is advancing two innovative platform programs, a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein.


Visit Website

ASMB Earnings

EPS -1.05 P/E Ratio 0.00
Previous Earnings Thu, Feb 28, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ASMB Dividend

Yield --
Ex-Date --
Pay Date --
History --

ASMB Charts

$14.78
52 Week Range
$48.04
Apr 15, 2019
Jun 18, 2018

15.22 0.39 0.00 0.00 ASMB NASDAQ -3.79 -33.94 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASMB&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASMB&exchange=NASDAQ&chart=1

Ascendis Pharma A/S [ASND]
$122.37 0.52 (0.42%)

ASND Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 5.73 Billion
ASND Description

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in the USA, Germany, and Switzerland and derives the majority of its revenue from the US.


Visit Website

ASND Earnings

EPS -0.76 P/E Ratio 0.00
Previous Earnings Wed, Nov 28, 2018
Latest Earnings Wed, Apr 3, 2019 (47 days ago)

ASND Dividend

Yield --
Ex-Date --
Pay Date --
History --

ASND Charts

$55.16
52 Week Range
$129.99
Dec 24, 2018
Mar 13, 2019

122.37 5.73 0.00 0.00 ASND NASDAQ -0.42 88.73 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASND&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASND&exchange=NASDAQ&chart=1

Arsanis Inc [ASNS]
$3.11 0.13 (4.01%)

ASNS Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 50 Million
ASNS Description

Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.


Visit Website

ASNS Earnings

EPS -0.66 P/E Ratio 0.00
Previous Earnings --
Latest Earnings Fri, Nov 9, 2018 (192 days ago)

ASNS Dividend

Yield --
Ex-Date --
Pay Date --
History --

ASNS Charts

$1.16
52 Week Range
$18.94
Nov 26, 2018
Jun 22, 2018

3.11 0.05 0.00 0.00 ASNS NASDAQ -4.01 21.48 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASNS&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ASNS&exchange=NASDAQ&chart=1

Athersys Inc [ATHX]
$1.97 0.06 (2.96%)

ATHX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 300 Million
ATHX Description

Athersys Inc is a clinical stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.


Visit Website

ATHX Earnings

EPS -0.09 P/E Ratio 0.00
Previous Earnings Thu, Mar 14, 2019
Latest Earnings Wed, May 8, 2019 (12 days ago)

ATHX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ATHX Charts

$1.39
52 Week Range
$2.79
Jan 22, 2019
Jun 6, 2018

1.97 0.30 0.00 0.00 ATHX NASDAQ -2.96 33.11 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATHX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATHX&exchange=NASDAQ&chart=1

Athenex Inc [ATNX]
$13.93 0.15 (1.07%)

ATNX Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.07 Billion
ATNX Description

Athenex Inc is a global biopharmaceutical company. It is dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company's mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The company has organized its business model into three segments, Oncology Innovation Platform, Commercial Platform and Global Supply Chain Platform with operations in both the U.S. and China.


Visit Website

ATNX Earnings

EPS -0.53 P/E Ratio 0.00
Previous Earnings Mon, Mar 11, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ATNX Dividend

Yield --
Ex-Date --
Pay Date --
History --

ATNX Charts

$9.44
52 Week Range
$19.97
May 1, 2019
Jul 5, 2018

13.93 1.07 0.00 0.00 ATNX NASDAQ -1.07 9.08 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATNX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATNX&exchange=NASDAQ&chart=1

Atara Biotherapeutics Inc [ATRA]
$23.99 0.18 (0.74%)

ATRA Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.11 Billion
ATRA Description

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. The company achieves this through two groups of product candidates, such as allogenic or third-party derived antigen-specific T-cells and molecularly targeted biologics.


Visit Website

ATRA Earnings

EPS -1.44 P/E Ratio 0.00
Previous Earnings Tue, Feb 26, 2019
Latest Earnings Thu, May 9, 2019 (11 days ago)

ATRA Dividend

Yield --
Ex-Date --
Pay Date --
History --

ATRA Charts

$23.99
52 Week Range
$51.45
May 17, 2019
May 21, 2018

23.99 1.11 0.00 0.00 ATRA NASDAQ -0.74 -31.96 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATRA&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=ATRA&exchange=NASDAQ&chart=1

Aurinia Pharmaceuticals Inc - Common Shares [AUPH]
$6.59 0.16 (2.49%)

AUPH Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 590 Million
AUPH Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.


Visit Website

AUPH Earnings

EPS -0.14 P/E Ratio 0.00
Previous Earnings Tue, Mar 19, 2019
Latest Earnings Tue, May 14, 2019 (6 days ago)

AUPH Dividend

Yield --
Ex-Date --
Pay Date --
History --

AUPH Charts

$5.08
52 Week Range
$7.64
Oct 24, 2018
Jan 15, 2019

6.59 0.59 0.00 0.00 AUPH NASDAQ 2.49 -3.65 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AUPH&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=AUPH&exchange=NASDAQ&chart=1

Autolus Therapeutics PLC [AUTL]
$22.59 0.45 (1.95%)

AUTL Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 1.04 Billion
AUTL Description

Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.


Visit Website

AUTL Earnings

EPS -0.69 P/E Ratio 0.00
Previous Earnings Mon, Feb 25, 2019
Latest Earnings Tue, May 14, 2019 (6 days ago)

AUTL Dividend

Yield --
Ex-Date --
Pay Date --
History --

AUTL Charts

$20.86
52 Week Range
$48.01
Jul 13, 2018
Nov 9, 2018